Morgan Stanley Raises its Price Target on Alnylam (ALNY)

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is one of the 10 Best Growth Stocks With Highest Upside Potential.

On July 10, 2026, Morgan Stanley raised the firm’s price target on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to $400 from $370 and kept an Equal Weight rating on the shares.

On July 9, Raymond James raised the firm’s price target on Alnylam to $468 from $420 and kept an Outperform rating on the shares. Raymond James said Ionis’ (IONS) failed Phase 3 ATTR-CM trial strengthens Alnylam’s competitive position by reducing a key rival to its TTR silencer franchise and improving the outlook for pricing. The firm also noted that the results may raise some risk for Alnylam’s next-generation nucresiran trial in patients receiving background tafamidis.

On June 29, H.C. Wainwright lowered the firm’s price target on Alnylam to $470 from $510 and kept a Buy rating on the shares. H.C. Wainwright reduced near-term estimates for Amvuttra but continued to estimate Alnylam’s TTR franchise growing to over $20B in annual revenues by 2040.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.

Disclosure: None. Follow Insider Monkey on Google News.